These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 352663)

  • 21. Antiestrogen treatment of breast cancer: an overview.
    Pearson OH; Manni A; Arafah BM
    Cancer Res; 1982 Aug; 42(8 Suppl):3424s-3429s. PubMed ID: 7044524
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Toxicity and adverse effects of Tamoxifen and other anti-estrogen drugs.
    Yang G; Nowsheen S; Aziz K; Georgakilas AG
    Pharmacol Ther; 2013 Sep; 139(3):392-404. PubMed ID: 23711794
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Current overview of EORTC clinical trials with tamoxifen.
    Heuson JC
    Cancer Treat Rep; 1976 Oct; 60(10):1463-6. PubMed ID: 1021227
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Clinical evaluation of the antioestrogenic agent tamoxifen in the treatment of metastatic breast cancer (author's transl)].
    Szepesi T; Czech W
    Wien Klin Wochenschr; 1978 Feb; 90(4):133-41. PubMed ID: 625990
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clinical review: Effect of endocrine therapies on bone in breast cancer patients.
    Santen RJ
    J Clin Endocrinol Metab; 2011 Feb; 96(2):308-19. PubMed ID: 21147884
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Tamoxifen for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group.
    Lancet; 1998 May; 351(9114):1451-67. PubMed ID: 9605801
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Anastrozole versus tamoxifen in postmenopausal women with ductal carcinoma in situ undergoing lumpectomy plus radiotherapy (NSABP B-35): a randomised, double-blind, phase 3 clinical trial.
    Margolese RG; Cecchini RS; Julian TB; Ganz PA; Costantino JP; Vallow LA; Albain KS; Whitworth PW; Cianfrocca ME; Brufsky AM; Gross HM; Soori GS; Hopkins JO; Fehrenbacher L; Sturtz K; Wozniak TF; Seay TE; Mamounas EP; Wolmark N
    Lancet; 2016 Feb; 387(10021):849-56. PubMed ID: 26686957
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Antiestrogen-induced remissions in stage IV breast cancer.
    Manni A; Trujillo J; Marshall JS; Pearson OH
    Cancer Treat Rep; 1976 Oct; 60(10):1445-50. PubMed ID: 1021225
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1-98.
    Coates AS; Keshaviah A; Thürlimann B; Mouridsen H; Mauriac L; Forbes JF; Paridaens R; Castiglione-Gertsch M; Gelber RD; Colleoni M; Láng I; Del Mastro L; Smith I; Chirgwin J; Nogaret JM; Pienkowski T; Wardley A; Jakobsen EH; Price KN; Goldhirsch A
    J Clin Oncol; 2007 Feb; 25(5):486-92. PubMed ID: 17200148
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Randomized comparison of tamoxifen versus diethylstilbestrol in estrogen receptor-positive or -unknown metastatic breast cancer: a Southeastern Cancer Study Group trial.
    Gockerman JP; Spremulli EN; Raney M; Logan T
    Cancer Treat Rep; 1986 Oct; 70(10):1199-203. PubMed ID: 3530447
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comparison of the short-term biological effects of 7alpha-[9-(4,4,5,5,5-pentafluoropentylsulfinyl)-nonyl]estra-1,3,5, (10)-triene-3,17beta-diol (Faslodex) versus tamoxifen in postmenopausal women with primary breast cancer.
    Robertson JF; Nicholson RI; Bundred NJ; Anderson E; Rayter Z; Dowsett M; Fox JN; Gee JM; Webster A; Wakeling AE; Morris C; Dixon M
    Cancer Res; 2001 Sep; 61(18):6739-46. PubMed ID: 11559545
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Reducing the risk for breast cancer recurrence after completion of tamoxifen treatment in postmenopausal women.
    Jahanzeb M
    Clin Ther; 2007 Aug; 29(8):1535-47. PubMed ID: 17919537
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Incidence and management of side effects associated with aromatase inhibitors in the adjuvant treatment of breast cancer in postmenopausal women.
    Mouridsen HT
    Curr Med Res Opin; 2006 Aug; 22(8):1609-21. PubMed ID: 16870085
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [The elucidation of the antiestrogen and antitumoral mechanisms of tamoxifen].
    Borgna JL
    Bull Cancer; 1994 Jan; 81(1):29-37. PubMed ID: 7949581
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Surveillance of patients treated with tamoxifen].
    Sananes S; Khairallah T; Touboul E; Salat-Baroux J; Uzan S
    Presse Med; 1996 Mar; 25(10):499-502. PubMed ID: 8685111
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Endocrine treatment options for advanced breast cancer--the role of fulvestrant.
    Robertson JF; Come SE; Jones SE; Beex L; Kaufmann M; Makris A; Nortier JW; Possinger K; Rutqvist LE
    Eur J Cancer; 2005 Feb; 41(3):346-56. PubMed ID: 15691633
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years' adjuvant tamoxifen: combined results of ABCSG trial 8 and ARNO 95 trial.
    Jakesz R; Jonat W; Gnant M; Mittlboeck M; Greil R; Tausch C; Hilfrich J; Kwasny W; Menzel C; Samonigg H; Seifert M; Gademann G; Kaufmann M; Wolfgang J;
    Lancet; 2005 Aug 6-12; 366(9484):455-62. PubMed ID: 16084253
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Clinical efficacy of tamoxifen.
    Robert NJ
    Oncology (Williston Park); 1997 Feb; 11(2 Suppl 1):15-20. PubMed ID: 9065922
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Burdens and benefits of adjuvant cyclophosphamide, methotrexate, and fluorouracil and tamoxifen for elderly patients with breast cancer: the International Breast Cancer Study Group Trial VII.
    Crivellari D; Bonetti M; Castiglione-Gertsch M; Gelber RD; Rudenstam CM; Thürlimann B; Price KN; Coates AS; Hürny C; Bernhard J; Lindtner J; Collins J; Senn HJ; Cavalli F; Forbes J; Gudgeon A; Simoncini E; Cortes-Funes H; Veronesi A; Fey M; Goldhirsch A
    J Clin Oncol; 2000 Apr; 18(7):1412-22. PubMed ID: 10735888
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Anti-oestrogen therapy for breast cancer: a trial of tamoxifen at two dose levels.
    Ward HW
    Br Med J; 1973 Jan; 1(5844):13-4. PubMed ID: 4567104
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.